W
WAVEMAN · COMPANY
TSHA · Taysha Gene Therapies, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

TSHA

Taysha Gene Therapies, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001806310
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$2.1M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
142
13F, latest reported quarter
REVENUE GROWTH
+17.3%
XBRL, annual
NET MARGIN
-1115.3%
CONVERSIONS · 180D
1
codes C/M, not in net · $32.5K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$2.1M over 180 days
-$1.2M over 90 days
below 68% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
142 funds added or opened last quarter
more than 77% of Pharma & Biotech
REVENUE
+17.3% year over year
more than 67% of Pharma & Biotech
MARGIN
-1115.3% net margin
below 90% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
142 funds added or opened positions in the latest 13F quarter, of 211 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +98.6%
+98.6%12M
-0%+48%+97%+146%2025-092025-102025-122026-032026-052026-072026-09 2026-07-10 · Nagendran Sukumar sold $1.2M2025-12-01 · Nagendran Sukumar sold $1.2M2026-01-12 · Nagendran Sukumar sold $942.0K2026-04-10 · Nagendran Sukumar sold $892.0K2026-01-23 · Nolan Sean P. sold $649.7K2025-09-10 · Nagendran Sukumar sold $646.0K2025-11-28 · Nagendran Sukumar sold $523.1K2026-01-23 · Nagendran Sukumar sold $423.4K2026-01-23 · Alam Kamran sold $375.1K2026-01-26 · Nolan Sean P. sold $190.4K2026-01-26 · Nagendran Sukumar sold $124.1K2026-01-26 · Alam Kamran sold $109.9K2026-02-04 · Alam Kamran sold $7.5K2026-07-10 · Nagendran Sukumar filed to sell $1.3M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $2.1M sold by insiders over 180 days, 142 funds added last quarter, $1.3M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Taysha Gene Therapies, Inc. insiders sold a net $2.1M of stock across 63 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Nagendran Sukumar
President and Head of R&D
SELL
2026-07-10
200,000.0
$1.2M
Nagendran Sukumar
President and Head of R&D
SELL
2026-04-10
200,000.0
$892.0K
Alam Kamran
CHIEF FINANCIAL OFFICER
SELL
2026-02-04
1,655.0
$7.5K
Nagendran Sukumar
President and Head of R&D
SELL
2026-01-26
26,918.0
$124.1K
Nolan Sean P.
Chief Executive Officer
SELL
2026-01-26
41,312.0
$190.4K
63 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 58 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Avoro Capital Advisors LLC
23,888,888.0 sh
$162.7M
RA CAPITAL MANAGEMENT, L.P.
23,555,648.0 sh
$160.4M
GOLDMAN SACHS GROUP INC
22,713,118.0 sh
$154.7M
BlackRock, Inc.
20,691,927.0 sh
$140.9M
Vestal Point Capital, LP
19,415,000.0 sh
$132.2M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Nagendran Sukumar
FILED 2026-07-10
$1.3M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Polen 5Perspectives Small Growth Fund
$629.1K POSITION · AS OF 2026-04-30
1.0%
Virtus Biotech Clinical Trials Etf
$304.6K POSITION · AS OF 2026-04-30
0.8%
ALPS Medical Breakthroughs ETF
$1.1M POSITION · AS OF 2026-02-28
0.8%
Direxion Daily S&P Biotech Bull 3X Shares
$2.1M POSITION · AS OF 2026-04-30
0.4%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$638.4K POSITION · AS OF 2026-04-30
0.3%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$25.2M POSITION · AS OF 2026-03-31
0.3%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 3 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release
2
Phase 3
2 ACTIVE
1
Multi-phase
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Sean Nolan
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$4.1M
$18.3M
$2.1M
+211%
—
2024
$4.7M
$4.7M
$3.1M
-2%
—
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$9.8M$8.3M$15.5M$2.5M
OPERATING INCOME$-110.5M$-91.5M$-72.4M$-162.4M
NET INCOME$-109.0M$-89.3M$-111.6M$-166.0M
EPS (DILUTED)-0.34-0.36-0.96-3.78
OPERATING CASH FLOW$-93.1M$-81.2M$-73.0M$-88.4M
CASH$319.8M$139.0M$143.9M$87.9M
LONG-TERM DEBT$50.1M$43.9M$40.5M$38.0M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →